All In Biotech

Drug Trial Radar · NCT05284799

Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.

Phase 2a, Randomized, Double-blind (Double-dummy), Controlled, Parallel-group Study to Evaluate the Immunogenicity and the Safety of the Concomitant Administration of OVX836 Influenza Vaccine and a Quadrivalent Inactivated Influenza Vaccine Given Intramuscularly as 2 Separate Injections in the Same Arm, in Comparison to Co-administration of Quadrivalent Inactivated Influenza Vaccine and Placebo and to Co-administration of OVX836 and Placebo Given Intramuscularly in Healthy Subjects.

Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Actual

Start

May 9, 2022

Primary completion

Jul 19, 2022

Study completion Dec 9, 2022

Sponsor

Lead sponsor
OsivaxIndustry
Sponsor type
Industry
Collaborators
Northern Beaches Clinical Research; Novotech (Australia) Pty Limited; Harmony Clinical Research BVBA
First posted
Mar 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The present study will evaluate the concomitant administration of a Quadrivalent Inactivated Influenza Vaccine with the highest dose level of OVX836 (480µg) tested in the clinic to date, for which the likelihood for interference with Quadrivalent Inactivated Influenza Vaccine is considered the highest.

Conditions

  • Influenza

Interventions

  • OVX836 480µgBiological

    One single administration intramuscularly at Day 1

  • Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)Biological

    One single administration intramuscularly at Day 1

  • PlaceboBiological

    One single administration intramuscularly at Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of seroconversion determined using Hemagglutination-Inhibition assay, for the four influenza strains contained in the Quadrivalent Influenza Vaccine.Time frame: At Day 29 versus pre-injection baseline (Day 1)
  2. Proportion of subjects achieving a titer ≥1:40 at Day 29 determined using Hemagglutination-Inhibition assay, for the four influenza strains contained in the Quadrivalent Influenza Vaccine.Time frame: At Day 29
  3. Number of Hemagglutination-Inhibition assay titers geometric mean ratios >2.5 for the four influenza strains contained in the Quadrivalent Influenza Vaccine.Time frame: At Day 29 versus pre-injection baseline (Day 1)
  4. Proportion of subjects reporting solicited local (Injection site redness, Injection site swelling, Injection site pain) and systemic signs and symptoms (Fatigue, Headache, Arthralgia, Malaise, Myalgia, Fever)Time frame: During 7 days after vaccine administration
  5. Proportion of subjects reporting unsolicited AEsTime frame: During 29 days after vaccine administration
  6. Proportion of subjects with Influenza-Like-Illness casesTime frame: During the whole study duration, 180 days
  7. Severity scores of Influenza-Like-Illness cases (as per Flu-PRO questionnaire)Time frame: During the whole study duration, 180 days
  8. Proportion of subjects reporting Serious Adverse EventsTime frame: During the whole study duration, 180 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Northern Beaches Clinical Research

    Brookvale, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.